# Filing Detail

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001140361-24-019505
Filing Date
2024-04-12
Accepted
2024-04-12 07:17:29
Documents
3

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | DEFA14A | ny20024347x2_defa14a.htm | DEFA14A | 11857
2 |  | ny20024347x2_nc01.jpg | GRAPHIC | 497202
3 |  | ny20024347x2_nc02.jpg | GRAPHIC | 329152
| Complete submission text file | 0001140361-24-019505.txt |  | 1150683

Mailing Address 200 TALCOTT AVENUE 2ND FLOOR WATERTOWN MA 02472
Business Address 200 TALCOTT AVENUE 2ND FLOOR WATERTOWN MA 02472 617-952-0555
Werewolf Therapeutics, Inc. (Filer) CIK: 0001785530 (see all company filings)

EIN.: 823523180 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-40366 | Film No.: 24839968
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)